Response to sirolimus in capillary lymphatic venous malformations and associated syndromes: Impact on symptomatology, quality of life, and radiographic response
Pediatric Blood & Cancer · 2023-04 · 70 (4)
DOI: 10.1002/pbc.30215 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 18.01.2023. Verfasst von Elissa R Engel und 15 weiteren Autor:innen. Beteiligte Einrichtung: Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Klippel-Trenaunay-Weber Syndrome, Vascular Malformations. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Capillary lymphatic venous malformations (CLVM) and associated syndromes, including Klippel–Trenaunay syndrome (KTS) and congenital lipomatous overgrowth, vascular malformation, epidermal nevi, skeletal, and spinal syndrome (CLOVES), are underrecognized disorders associated with high morbidity from chronic pain, recurrent infections, bleeding, and clotting complications. The rarity of these disorders and heterogeneity of clinical presentations make large‐scale randomized clinical drug trials challenging. Identification of PIK3CA (phosphatidylinositol‐4,5‐bisphosphate 3‐kinase catalytic subunit alpha [gene]) mutations in CLVM has made targeted medications, such as sirolimus, attractive treatment options. The aim of this study was to investigate the safety and efficacy of sirolimus therapy in CLVM. Procedure A combined prospective and retrospective cohort of pediatric and young adult patients with CLVM treated with sirolimus was evaluated for disease response, including symptom improvement, quality of life (QOL), and radiologic response. Sirolimus dosing regimens and toxicities were also assessed.
Results
Twenty‐nine patients with CLVM, including KTS and CLOVES, were included. Ninety‐three percent of patients reported improved QOL, and 86% had improvement in at least one symptom. Most significantly, improvement was noted in 100% of patients with bleeding and 89% with thrombotic complications with corresponding decreases in mean D‐dimer ( p = .008) and increases in mean fibrinogen ( p = .016). No patients had progressive disease on sirolimus. Most common side effects included neutropenia, lymphopenia, infection, and aphthous ulcers/stomatitis. No toxicities were life‐threatening, and none required long‐term discontinuation of sirolimus.
Conclusion
Sirolimus appears to be effective at reducing complications and improving QOL in patients with CLVM and associated syndromes. In this patient cohort, sirolimus was well tolerated and resulted in few treatment‐related toxicities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Division of Hematology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
- Division of Oncology, Comprehensive Vascular Anomalies Program, Children's Hospital of Philadelphia and Perelman School of Medicine and the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Paediatrics Monash University, Royal Children's Hospital, Melbourne, New South Wales, Australia.
- Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California, USA.
- Department of Dermatology and Pediatrics, Mayo Clinic and Mayo Clinic Children's Center, Rochester, Minnesota, USA.
ORCID-Profile: Elissa R Engel, Adrienne Hammill, Michael Jeng, Deborah Schiff, Kiersten Ricci
Zitieren
APA
Engel, E. R., Hammill, A., Adams, D., Phillips, R. J., Jeng, M., Tollefson, M. M., Iacobas, I., Schiff, D., Greenberger, S., Kelly, M., Frieden, I., Zaghloul, N., Drolet, B., Geddis, A., Goldenberg, D., & Ricci, K. (2023). Response to sirolimus in capillary lymphatic venous malformations and associated syndromes: Impact on symptomatology, quality of life, and radiographic response. Pediatric Blood & Cancer, 70(4). https://doi.org/10.1002/pbc.30215
Vancouver
Engel ER, Hammill A, Adams D, Phillips RJ, Jeng M, Tollefson MM, et al. Response to sirolimus in capillary lymphatic venous malformations and associated syndromes: Impact on symptomatology, quality of life, and radiographic response. Pediatric Blood & Cancer. 2023;70(4). doi:10.1002/pbc.30215
BibTeX
@article{Engel2023,
author = {Engel, Elissa R and Hammill, Adrienne and Adams, Denise and Phillips, Roderic J and Jeng, Michael and Tollefson, Megha M and Iacobas, Ionela and Schiff, Deborah and Greenberger, Shoshana and Kelly, Michael and Frieden, Ilona and Zaghloul, Nibal and Drolet, Beth and Geddis, Amy and Goldenberg, Dov and Ricci, Kiersten},
title = {Response to sirolimus in capillary lymphatic venous malformations and associated syndromes: Impact on symptomatology, quality of life, and radiographic response},
journal = {Pediatric Blood & Cancer},
year = {2023},
volume = {70},
number = {4},
doi = {10.1002/pbc.30215}
}
EUVIMED